Developer docs
API playgroundTry for free, no card

Search company profiles

Etiometry

Full company profile

uuid0000nc3

Namestring
Etiometry
Legal namestring
Etiometry Inc.
Websiteurl
etiometry.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Etiometry Inc. is a Boston-based, privately held healthcare software company founded in 2010 that builds an FDA-cleared clinical intelligence platform for high-acuity care teams in hospital intensive care units. Its platform aggregates high-frequency physiologic data from ventilators, bedside monitors, labs, EHR systems, and other sources into a unified visualization layer and computes four FDA-cleared adjunctive risk indices (IDO2 for inadequate oxygen delivery, IVCO2 for inadequate CO2 ventilation, HLA for hyperlactatemia, and ACD for acidosis), plus a newly cleared automated cardiogenic shock classification tool, all derived from more than 150 million hours of de-identified patient data. The company complements these risk analytics with clinical pathway automation aligned to hospital-specific protocols and a quality improvement application, and it integrates directly with Epic and Cerner EHRs.

Etiometry sells exclusively through a direct enterprise sales motion to academic medical centers, children's hospitals, and heart centers, with quote-based annual subscriptions that vary by hospital size and ICU count, bundled with implementation support and an ongoing adoption program. The platform is deployed in more than 175 ICUs across 50+ hospitals globally, holds 11 FDA clearances plus four Health Canada approvals and CE markings, and is protected by ten granted US patents. Its go-to-market is anchored by clinical evidence partnerships with leading institutions such as Boston Children's Hospital, Washington University School of Medicine, UT Southwestern, and Children's National Hospital, which both validate the product and generate the peer-reviewed outcomes that support sales cycles. In 2026 the company announced a strategic partnership with Radiometer Medical ApS to integrate acute care blood gas and electrolyte diagnostics into the platform, extending its ecosystem beyond traditional physiologic monitoring.

Short descriptiontext

Etiometry is a Boston-based, privately held clinical intelligence software company that sells an FDA-cleared, AI-driven platform aggregating ICU physiologic data and computing proprietary risk indices, deployed in 175+ ICUs across 50+ hospitals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical intelligence software, ICU patient monitoring, clinical decision support, physiologic risk analytics, critical care software
Industry1 code
PRIMARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
NAICS code1 code
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Services-Prepackaged Software7372
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Clinical Intelligence Software for Critical Care
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Intelligence Software Platform
TypeSubscription Recurring
Description

Etiometry generates revenue through licensing its AI-driven clinical intelligence platform to hospitals and healthcare systems. The platform is sold as a subscription or contract basis with implementation and support services included. Pricing is quote-based and varies by hospital size and ICU count. The company provides ongoing adoption program at no additional cost as part of the contract.

etiometry.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise hospital licensing - custom pricing
ModelSubscriptionBilling cadenceAnnual
Notes

Pricing varies based on hospital size, number of ICUs, and implementation scope. Quote-based sales process.

etiometry.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Etiometry develops and sells an FDA-cleared clinical intelligence platform for hospital intensive care units (ICUs) that aggregates high-frequency physiologic data from ventilators, monitors, labs, and EHR systems. The platform computes FDA-cleared adjunctive risk indices (IDO2, IVCO2, HLA, ACD, and the Cardiogenic Shock Tool), provides data visualization, automates hospital-defined clinical pathways, and supports quality improvement initiatives. It is licensed to academic medical centers, children's hospitals, and cardiac care programs on a subscription basis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Reduce ICU Length of Stay by up to 36%
+7 more records
Product overview1 text field

Etiometry offers a unified clinical intelligence platform for high-acuity care teams, centered on the Etiometry Platform which consolidates data aggregation and visualization, FDA-cleared risk analytics (IDO2, IVCO2, HLA, ACD, and Cardiogenic Shock indices), clinical pathway automation, and quality improvement modules. The platform is accessed via bedside displays, workstations, central command centers, or EHR single sign-on. The Heart Center Solutions bundle provides specialized cardiac care workflows. All components are built on over 150 million hours of de-identified patient data and are explicitly adjunctive to clinician judgment, not replacing monitoring devices or alarms.

Product and service2 records
1Etiometry Platform
CategoryClinical Intelligence Platform
Description

End-to-end FDA-cleared clinical intelligence platform for ICU clinical data collection, analysis, visualization, and archiving. It aggregates data from ventilators, monitors, EHRs, labs, and peripheral devices, and delivers FDA-cleared risk indices, clinical pathway automation, and quality improvement capabilities for high-acuity care teams in academic medical centers and children's hospitals.

2Etiometry IDO2 Index
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-17
Description

Radiometer Medical ApS partnered with Etiometry Inc to integrate acute care diagnostics with AI-based clinical decision-support software. This strategic partnership combines Radiometer's blood gas and electrolyte analyzer technology with Etiometry's clinical intelligence platform to enhance acute care diagnostics workflow.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Mindray is a large global patient monitoring vendor with a significant U.S. acute care presence. It competes for the same ICU monitoring data feeds and is increasingly layering clinical decision-support analytics, paralleling Etiometry's positioning from the hardware side.

TypeBroad incumbent
Description

Philips is a global incumbent in ICU patient monitoring (IntelliVue, PIC iX) and acute care analytics. Comparable to Etiometry as an integrated monitoring-and-analytics platform vendor serving the same ICUs, but at much larger scale and as part of a broader hospital portfolio.

TypeEmerging player
Description

Hicuity Health is one of the largest tele-ICU providers in the U.S., delivering remote critical care services to partner hospitals. It is adjacent rather than directly competitive — Etiometry provides the on-site clinical intelligence platform while Hicuity provides the remote clinician staffing layer — but both target the same ICU outcomes improvement budgets.

TypeBroad incumbent
Description

GE HealthCare is a major ICU patient monitoring incumbent (CARESCAPE, ICU central stations) and has been layering analytics and AI onto its monitoring platform. Comparable to Etiometry on the monitoring data layer, though Etiometry's FDA-cleared risk algorithms are more decision-support specialized.

TypeDirect peer
Description

Ambient Clinical Analytics sells AWARE, an FDA-cleared ICU clinical decision support platform that aggregates bedside data and surfaces critical-care analytics. It directly competes with Etiometry in the same ICU clinical intelligence category.

TypeEmerging player
Description

Qventus applies AI to hospital operations including ICU flow, length of stay reduction, and discharge planning. It overlaps with Etiometry on AI-driven ICU optimization but is broader in scope (perioperative, inpatient, ED) and less focused on physiology-based risk indices.

TypeBroad incumbent
Description

Baxter acquired Cheetah Medical in 2019 (where Etiometry's CEO Shane Cooke was previously CSO) and now sells the Starling hemodynamic monitoring system. Baxter is a broader medtech incumbent that competes for ICU monitoring and decision-support budget.

TypeBroad incumbent
Description

Edwards is a dominant hemodynamic monitoring incumbent (FloTrac, ClearSight, HemoSphere) used in the same ICUs where Etiometry's risk indices operate. It competes for clinical attention and budget around advanced ICU monitoring, though its core is hardware sensors rather than analytics software.

TypeDirect peer
Description

MIC's Sickbay platform is a clinical decision support and data aggregation platform for ICUs, integrating waveforms and EMR data and providing FDA-cleared analytics. It is the closest head-to-head competitor to Etiometry in ICU clinical intelligence software.

10Nihon Kohden
TypeBroad incumbent
Description

Nihon Kohden is a patient monitoring incumbent with strong neurology and ICU presence, including its own AI-based early warning work. Comparable as a monitoring-plus-analytics vendor serving similar critical-care buyers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Etiometry

Clinical Intelligence Software for Critical Careetiometry.com

Etiometry is a Boston-based, privately held clinical intelligence software company that sells an FDA-cleared, AI-driven platform aggregating ICU physiologic data and computing proprietary risk indices, deployed in 175+ ICUs across 50+ hospitals.

What Etiometry does

Etiometry Inc. is a Boston-based, privately held healthcare software company founded in 2010 that builds an FDA-cleared clinical intelligence platform for high-acuity care teams in hospital intensive care units. Its platform aggregates high-frequency physiologic data from ventilators, bedside monitors, labs, EHR systems, and other sources into a unified visualization layer and computes four FDA-cleared adjunctive risk indices (IDO2 for inadequate oxygen delivery, IVCO2 for inadequate CO2 ventilation, HLA for hyperlactatemia, and ACD for acidosis), plus a newly cleared automated cardiogenic shock classification tool, all derived from more than 150 million hours of de-identified patient data. The company complements these risk analytics with clinical pathway automation aligned to hospital-specific protocols and a quality improvement application, and it integrates directly with Epic and Cerner EHRs.

Etiometry sells exclusively through a direct enterprise sales motion to academic medical centers, children's hospitals, and heart centers, with quote-based annual subscriptions that vary by hospital size and ICU count, bundled with implementation support and an ongoing adoption program. The platform is deployed in more than 175 ICUs across 50+ hospitals globally, holds 11 FDA clearances plus four Health Canada approvals and CE markings, and is protected by ten granted US patents. Its go-to-market is anchored by clinical evidence partnerships with leading institutions such as Boston Children's Hospital, Washington University School of Medicine, UT Southwestern, and Children's National Hospital, which both validate the product and generate the peer-reviewed outcomes that support sales cycles. In 2026 the company announced a strategic partnership with Radiometer Medical ApS to integrate acute care blood gas and electrolyte diagnostics into the platform, extending its ecosystem beyond traditional physiologic monitoring.

Etiometry firmographics

Firmographics
Name
Etiometry
Legal name
Etiometry Inc.
Website
https://etiometry.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
Etiometry is a Boston-based, privately held clinical intelligence software company that sells an FDA-cleared, AI-driven platform aggregating ICU physiologic data and computing proprietary risk indices, deployed in 175+ ICUs across 50+ hospitals.
Ownership category
akta.pro rank

Etiometry industry classification

Industry
Product category
Clinical Intelligence Software for Critical Care
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Services-Prepackaged Software (7372), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Clinical intelligence software
  • ICU patient monitoring
  • Clinical decision support
  • Physiologic risk analytics
  • Critical care software

Where Etiometry is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Etiometry business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Clinical Intelligence Software Platform: Etiometry generates revenue through licensing its AI-driven clinical intelligence platform to hospitals and healthcare systems. The platform is sold as a subscription or contract basis with implementation and support services included. Pricing is quote-based and varies by hospital size and ICU count. The company provides ongoing adoption program at no additional cost as part of the contract.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise hospital licensing - custom pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Etiometry product offering

Product offering

Core offering

Etiometry develops and sells an FDA-cleared clinical intelligence platform for hospital intensive care units (ICUs) that aggregates high-frequency physiologic data from ventilators, monitors, labs, and EHR systems. The platform computes FDA-cleared adjunctive risk indices (IDO2, IVCO2, HLA, ACD, and the Cardiogenic Shock Tool), provides data visualization, automates hospital-defined clinical pathways, and supports quality improvement initiatives. It is licensed to academic medical centers, children's hospitals, and cardiac care programs on a subscription basis.

Product overview

Etiometry offers a unified clinical intelligence platform for high-acuity care teams, centered on the Etiometry Platform which consolidates data aggregation and visualization, FDA-cleared risk analytics (IDO2, IVCO2, HLA, ACD, and Cardiogenic Shock indices), clinical pathway automation, and quality improvement modules. The platform is accessed via bedside displays, workstations, central command centers, or EHR single sign-on. The Heart Center Solutions bundle provides specialized cardiac care workflows. All components are built on over 150 million hours of de-identified patient data and are explicitly adjunctive to clinician judgment, not replacing monitoring devices or alarms.

Differentiator

Problem solved

Functional benefit

Products and services

  • Etiometry Platform End-to-end FDA-cleared clinical intelligence platform for ICU clinical data collection, analysis, visualization, and archiving. It aggregates data from ventilators, monitors, EHRs, labs, and peripheral devices, and delivers FDA-cleared risk indices, clinical pathway automation, and quality improvement capabilities for high-acuity care teams in academic medical centers and children's hospitals.
  • Etiometry IDO2 Index

Quantifiable outcome

  • Reduce ICU Length of Stay by up to 36%
  • +7 more outcomes

Companies that use Etiometry

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Etiometry technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability2 records

Feature8 records

Etiometry partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Radiometer Medical ApScoreTechnology or Integration · 17 June 2026Radiometer Medical ApS partnered with Etiometry Inc to integrate acute care diagnostics with AI-based clinical decision-support software. This strategic partnership combines Radiometer's blood gas and electrolyte analyzer technology with Etiometry's clinical intelligence platform to enhance acute care diagnostics workflow.

Scale indicators10 records

Recent moves3 records

Expansion highlights6 records

Etiometry competitors and assessment

Company assessment

Broad incumbents

  • Mindray: Mindray is a large global patient monitoring vendor with a significant U.S. acute care presence. It competes for the same ICU monitoring data feeds and is increasingly layering clinical decision-support analytics, paralleling Etiometry's positioning from the hardware side.
  • Philips (Patient Monitoring): Philips is a global incumbent in ICU patient monitoring (IntelliVue, PIC iX) and acute care analytics. Comparable to Etiometry as an integrated monitoring-and-analytics platform vendor serving the same ICUs, but at much larger scale and as part of a broader hospital portfolio.
  • GE HealthCare: GE HealthCare is a major ICU patient monitoring incumbent (CARESCAPE, ICU central stations) and has been layering analytics and AI onto its monitoring platform. Comparable to Etiometry on the monitoring data layer, though Etiometry's FDA-cleared risk algorithms are more decision-support specialized.
  • Baxter International: Baxter acquired Cheetah Medical in 2019 (where Etiometry's CEO Shane Cooke was previously CSO) and now sells the Starling hemodynamic monitoring system. Baxter is a broader medtech incumbent that competes for ICU monitoring and decision-support budget.
  • Edwards Lifesciences: Edwards is a dominant hemodynamic monitoring incumbent (FloTrac, ClearSight, HemoSphere) used in the same ICUs where Etiometry's risk indices operate. It competes for clinical attention and budget around advanced ICU monitoring, though its core is hardware sensors rather than analytics software.
  • Nihon Kohden: Nihon Kohden is a patient monitoring incumbent with strong neurology and ICU presence, including its own AI-based early warning work. Comparable as a monitoring-plus-analytics vendor serving similar critical-care buyers.

Emerging players

  • Hicuity Health: Hicuity Health is one of the largest tele-ICU providers in the U.S., delivering remote critical care services to partner hospitals. It is adjacent rather than directly competitive — Etiometry provides the on-site clinical intelligence platform while Hicuity provides the remote clinician staffing layer — but both target the same ICU outcomes improvement budgets.
  • Qventus: Qventus applies AI to hospital operations including ICU flow, length of stay reduction, and discharge planning. It overlaps with Etiometry on AI-driven ICU optimization but is broader in scope (perioperative, inpatient, ED) and less focused on physiology-based risk indices.

Direct peers

  • Ambient Clinical Analytics: Ambient Clinical Analytics sells AWARE, an FDA-cleared ICU clinical decision support platform that aggregates bedside data and surfaces critical-care analytics. It directly competes with Etiometry in the same ICU clinical intelligence category.
  • Medical Informatics Corp: MIC's Sickbay platform is a clinical decision support and data aggregation platform for ICUs, integrating waveforms and EMR data and providing FDA-cleared analytics. It is the closest head-to-head competitor to Etiometry in ICU clinical intelligence software.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Etiometry social profiles

Digital presence

Etiometry compliance and trust

Trust signal

Compliance2 records

Etiometry financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Etiometry leadership team

Management profile

Number of profiles

Profiles10 records

Etiometry funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Etiometry M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Etiometry

What does Etiometry do?

Etiometry develops and sells an FDA-cleared clinical intelligence platform for hospital intensive care units (ICUs) that aggregates high-frequency physiologic data from ventilators, monitors, labs, and EHR systems. The platform computes FDA-cleared adjunctive risk indices (IDO2, IVCO2, HLA, ACD, and the Cardiogenic Shock Tool), provides data visualization, automates hospital-defined clinical pathways, and supports quality improvement initiatives. It is licensed to academic medical centers, children's hospitals, and cardiac care programs on a subscription basis.

Is Etiometry a public or private company?

Etiometry is a private company. It is classified as venture growth investor backed and is currently operating.

When was Etiometry founded?

Etiometry was founded in 2010. It employs 51 to 100 people.

Where is Etiometry based?

Etiometry is headquartered in Boston, United States, in the North America region.

How does Etiometry make money?

One revenue line is on record: clinical Intelligence Software Platform.

Who are Etiometry's main competitors?

Broad incumbents on record are Mindray, Philips (Patient Monitoring), GE HealthCare, Baxter International, Edwards Lifesciences and Nihon Kohden. Emerging players are Hicuity Health and Qventus. Direct peers are Ambient Clinical Analytics and Medical Informatics Corp.

Does Etiometry have an API?

No public API is recorded for Etiometry.

What industry is Etiometry in?

Etiometry's product category is Clinical Intelligence Software for Critical Care. Its primary akta.pro industry code is HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration). Its NAICS code is 33451 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogHamilton Medical, Inc. and Etiometry Partner to Advance Data-Driven Respiratory Care in the ICUHamilton Medical and Etiometry announced a U.S. partnership to combine ventilation technology with AI-driven clinical intelligence for ICU respiratory care. The collaboration aims to help clinicians identify meaningful changes in patient condition and make timely decisions, initially focusing on ARDS and oxygenation criteria. The companies seek to move ICU teams from reactive to proactive, personalized care.PR NewswireBlood Gas & Electrolyte Analyzers Market Forecast to Reach US$ 3.3B by 2030 at 5% CAGR, Wissen ResearchThe global blood gas and electrolyte analyzers market is projected to grow from USD 2.7 billion in 2025 to USD 3.3 billion by 2030, registering a 5% CAGR, driven by rising critical illnesses, respiratory disorders, sepsis, and technological advancements in cartridge-based and point-of-care systems. Key industry developments include strategic partnerships such as Radiometer Medical ApS partnering with Etiometry Inc to integrate acute care diagnostics with AI-based clinical decision-support software, and EDAN Instruments showcasing its expanding portfolio including the i500 multi-parameter analyzer. North America currently leads the market due to advanced healthcare infrastructure, while Asia-Pacific is expected to register the fastest growth, with hospitals, ICUs, and emergency departments remaining the primary end users.Mpo-magFDA Clears Etiometry’s Solution for Automating Hospital-Specific Cardiogenic Shock ClassificationEtiometry received FDA clearance for its Cardiogenic Shock Tool, the first solution to automate hospital-specific cardiogenic shock classification and tracking using physiologic monitoring data. The tool integrates with EHRs and supports SCAI staging, addressing that 50% or more of cardiogenic shock cases go undocumented. The company has secured 11 FDA clearances.PR NewswireBlood Gas & Electrolyte Analyzers Market Forecast to Reach US$ 3.3B by 2030 at 5% CAGR, Wissen ResearchThe global blood gas and electrolyte analyzers market is projected to grow from $2.7 billion in 2025 to $3.3 billion by 2030, a 5% CAGR, according to Wissen Research. Demand is driven by rising critical illnesses, sepsis, and respiratory disorders, with point-of-care and multi-parameter systems gaining adoption. North America leads, while Asia-Pacific is expected to see the fastest growth.Business Wire BlogEtiometry Receives a First-Ever FDA Clearance for Automating Hospital-Specific Cardiogenic Shock Classification and TrackingEtiometry has received the first-ever FDA clearance for its Cardiogenic Shock Tool, an AI-driven solution that automates hospital-specific classification and tracking of cardiogenic shock using physiologic monitoring data. This platform integrates with electronic health records to provide continuous situational awareness, aiming to improve clinical decision-making and operational outcomes such as reduced length of stay. The clearance reinforces Etiometry's position in providing clinical intelligence solutions for critical care.Business Wire BlogEtiometry Expands Evidence Base with New Adult Data Demonstrating Clinical Value Across Critical Care SettingsEtiometry announced new clinical evidence from a study conducted at University of Texas Southwestern Medical Center in Dallas, presented at the 2026 Society of Thoracic Surgeons Annual Meeting in New Orleans, demonstrating the platform's ability to identify patient-specific risk in adult critical care. The study evaluated 71 adult patients undergoing pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension and found that continuous monitoring with the Etiometry Platform identified associations between higher inadequate delivery of oxygen levels within the first 24 hours postoperatively and prolonged hospital length of stay. The findings expand Etiometry's evidence base beyond its established pediatric indications into adult critical care settings, building on the platform's FDA clearance for adult use obtained in January 2023.Business Wire BlogEtiometry Wins Best in Class AI in Patient Care Award at 7th Annual Digital Health Hub Foundation Awards at HLTHEtiometry, a Boston-based AI-driven clinical intelligence company, won the 2025 Digital Health Hub Award for Best in Class - AI in Patient Care at the HLTH conference, selected from over 1,800 applicants. The award recognizes the company's platform that transforms hospital data into real-time insights for critical care clinicians, now deployed across more than 50 hospitals globally. Etiometry reported 2.5 million clinician interactions in 2024 with platform logins reaching 200,000, a 50% increase from 2023, and expects to exceed 3 million interactions and 250,000 logins in 2025.Roots AnalysisTele-Intensive Care Unit Market Size & Industry Report 2035The global tele-intensive care unit market is projected to grow from USD 3.5 billion in 2024 to USD 15.40 billion by 2035, driven by the increasing adoption of telehealth services for remote critical care consultation. Key industry developments include Philips launching a new tele-critical care program and Etiometry receiving FDA clearance for its critical care platform with enhanced cybersecurity features.Respiratory TherapyPICU Observed Shorter Ventilator Duration Using Etiometry PlatformA study at Children’s Hospital of Alabama found that implementing Etiometry’s automated spontaneous breathing trial tool reduced mechanical ventilation duration by 30% and hospital length of stay by 20% for pediatric cardiac ICU patients. The platform utilizes real-time clinical data to standardize extubation readiness tests, leading to faster patient recovery and potential cost savings for the hospital.Children's National HospitalPredictive analytics elevates NICU patient careChildren’s National Hospital is enhancing neonatal intensive care unit (NICU) patient management by implementing the Etiometry predictive analytics platform and EC10 hardware to monitor vital signs in real-time. A $35,000 grant from the Founders Auxiliary Board at Children’s National funds equipping each room with an EC10 device and cloud connectivity modules to ensure consistent data capture. This initiative has streamlined research processes and enabled clinical studies linking oxygen treatment compliance to conditions like retinopathy of prematurity.